Biotech Pest Management

biotechpestmanagement.com

Biotech Pest Management is a Charleston, South Carolina exterminator specializing in pest control services for residential and commercial property; including bed bug, mosquito and wildlife management.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

TFF PHARMACEUTICALS AND FELIX BIOTECHNOLOGY SIGN LETTER OF INTENT FOR A COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENT

Felix Biotechnology, Inc. | November 06, 2020

news image

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, and Felix Biotechnology, Inc., a clinical stage, biotherapeutic-based antibiotic development company, today jointly announce that both companies have entered into a letter of intent (LOI) which reflects the parties’ non-binding agreement in principle to negotiate and enter ...

Read More

MEDICAL

EMMAUS LIFE SCIENCES ANNOUNCES LAUNCH OF FULL-SERVICE TELEHEALTH SOLUTION

Emmaus Life Sciences, Inc. | April 12, 2022

news image

Emmaus Life Sciences, Inc. (OTQXC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the launch of an innovative full-service telehealth solution with its strategic partners, including Asembia LLC, US Bioservices Corporation and UpScriptHealth. The telehealth program capitalizes on the expansion of telemedicine in the U.S. to afford patients and providers on-line access to Endari®, the company's prescription-grade L-gl...

Read More

CELL AND GENE THERAPY

GRITSTONE BIO AND CEPI EXPAND VACCINE AGREEMENT TO TACKLE OMICRON VARIANT

Gritstone bio | December 07, 2021

news image

Gritstone bio, Inc. a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, and CEPI, the Coalition for Epidemic Preparedness Innovations, announced the expansion of their agreement in order to support the development of a self-amplifying mRNA vaccine designed to tackle the Omicron COVID-19 variant. CEPI will provide up to $5 million in additional funding to conduct a Phase 1 clinical trial of Gritstone’s Omicron vaccine ...

Read More

INDUSTRIAL IMPACT

ENVERIC BIOSCIENCES ADVANCES DRUG DEVELOPMENT FOR MENTAL HEALTH INDICATIONS AND INTELLECTUAL PROPERTY PORTFOLIO

Enveric Biosciences, Inc | July 14, 2022

news image

Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property advances achieved during the first half of 2022. “The first half of 2022 was foundationally successful for Enveric. We validated and executed on the corporate premise that we can deploy Psy...

Read More
news image

TFF PHARMACEUTICALS AND FELIX BIOTECHNOLOGY SIGN LETTER OF INTENT FOR A COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENT

Felix Biotechnology, Inc. | November 06, 2020

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, and Felix Biotechnology, Inc., a clinical stage, biotherapeutic-based antibiotic development company, today jointly announce that both companies have entered into a letter of intent (LOI) which reflects the parties’ non-binding agreement in principle to negotiate and enter ...

Read More
news image

MEDICAL

EMMAUS LIFE SCIENCES ANNOUNCES LAUNCH OF FULL-SERVICE TELEHEALTH SOLUTION

Emmaus Life Sciences, Inc. | April 12, 2022

Emmaus Life Sciences, Inc. (OTQXC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the launch of an innovative full-service telehealth solution with its strategic partners, including Asembia LLC, US Bioservices Corporation and UpScriptHealth. The telehealth program capitalizes on the expansion of telemedicine in the U.S. to afford patients and providers on-line access to Endari®, the company's prescription-grade L-gl...

Read More
news image

CELL AND GENE THERAPY

GRITSTONE BIO AND CEPI EXPAND VACCINE AGREEMENT TO TACKLE OMICRON VARIANT

Gritstone bio | December 07, 2021

Gritstone bio, Inc. a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, and CEPI, the Coalition for Epidemic Preparedness Innovations, announced the expansion of their agreement in order to support the development of a self-amplifying mRNA vaccine designed to tackle the Omicron COVID-19 variant. CEPI will provide up to $5 million in additional funding to conduct a Phase 1 clinical trial of Gritstone’s Omicron vaccine ...

Read More
news image

INDUSTRIAL IMPACT

ENVERIC BIOSCIENCES ADVANCES DRUG DEVELOPMENT FOR MENTAL HEALTH INDICATIONS AND INTELLECTUAL PROPERTY PORTFOLIO

Enveric Biosciences, Inc | July 14, 2022

Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property advances achieved during the first half of 2022. “The first half of 2022 was foundationally successful for Enveric. We validated and executed on the corporate premise that we can deploy Psy...

Read More